Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-09-03, Stock:NVS, The news for the past five days is as follows:
2019-08-26: NEWS1: Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study.NEWS2: Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study.NEWS3: Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study.
2019-08-27: NEWS1: Lilly's (LLY) Taltz Gets FDA Nod for Ankylosing Spondylitis.NEWS2: Lilly's (LLY) Taltz Gets FDA Nod for Ankylosing Spondylitis.NEWS3: Amgen to Buy Celgene's Otezla: 5 ETF Drugs.NEWS4: Amgen to Buy Celgene's Otezla: 5 ETF Drugs.NEWS5: Has Novartis (NVS) Outpaced Other Medical Stocks This Year?.NEWS6: Has Novartis (NVS) Outpaced Other Medical Stocks This Year?.NEWS7: Lilly's (LLY) Taltz Gets FDA Nod for Ankylosing Spondylitis.NEWS8: Amgen to Buy Celgene's Otezla: 5 ETF Drugs.NEWS9: Has Novartis (NVS) Outpaced Other Medical Stocks This Year?.
2019-08-28: NEWS1: J&J (JNJ) Loses Landmark Opioid Case: What's Next for Pharmaceuticals?.NEWS2: J&J (JNJ) Loses Landmark Opioid Case: What's Next for Pharmaceuticals?.NEWS3: Ionis (IONS) Out-licenses Hepatitis B Virus Program to Glaxo.NEWS4: Ionis (IONS) Out-licenses Hepatitis B Virus Program to Glaxo.NEWS5: J&J (JNJ) Loses Landmark Opioid Case: What's Next for Pharmaceuticals?.NEWS6: Ionis (IONS) Out-licenses Hepatitis B Virus Program to Glaxo.NEWS7: AstraZeneca's Fasenra Gets Orphan Drug Status for New Disease.NEWS8: AstraZeneca's Fasenra Gets Orphan Drug Status for New Disease.NEWS9: AstraZeneca's Fasenra Gets Orphan Drug Status for New Disease.
2019-08-29: NEWS1: IMPORTANT SHAREHOLDER NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm.NEWS2: Roche's Tecentriq Combo Gets EU Nod for Critical Breast Cancer.NEWS3: Roche's Tecentriq Combo Gets EU Nod for Critical Breast Cancer.NEWS4: EQUITY ALERT: Rosen Law Firm Continues To Investigate Securities Claims Against Novartis AG – NVS.NEWS5: Roche's Tecentriq Combo Gets EU Nod for Critical Breast Cancer.NEWS6: Forget Pfizer, Add These Big Drugmakers to Your Portfolio.NEWS7: Forget Pfizer, Add These Big Drugmakers to Your Portfolio.NEWS8: Forget Pfizer, Add These Big Drugmakers to Your Portfolio.
2019-08-30: NEWS1: AstraZeneca's Lupus Drug Meets Primary Endpoint in Study.NEWS2: AstraZeneca's Lupus Drug Meets Primary Endpoint in Study.NEWS3: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Novartis AG (NVS).NEWS4: AstraZeneca's Lupus Drug Meets Primary Endpoint in Study.NEWS5: Novartis' (NVS) MS Drug Achieves Goals in Late-Stage Studies.NEWS6: Novartis' (NVS) MS Drug Achieves Goals in Late-Stage Studies.NEWS7: Pharma Stock Roundup: JNJ's Opioid Lawsuit, Regulatory Nod for LLY, BMY, RHHBY Drugs.NEWS8: Health Care Sector Update for 08/30/2019: AKTX, NVS, SNY, NKTR, JNJ, PFE, MRK, ABT, AMGN.NEWS9: Health Care Sector Update for 08/30/2019: AKTX, NVS, SNY, NKTR, JNJ, PFE, MRK, ABT, AMGN.NEWS10: The Daily Biotech Pulse: Genmab-Novartis Multiple Sclerosis Drug Aces Late-Stage Studies, Akari Nets Orphan Drug Designation.NEWS11: Novartis' (NVS) MS Drug Achieves Goals in Late-Stage Studies.NEWS12: Novartis takes aim at Roche's star MS drug.NEWS13: UPDATE 2-Novartis takes aim at Roche's star MS drug.

Answer: Decrease